How cells switch HIPK2 on and off

Cell Death and Differentiation

Volumn 16, Issue 2, 2009, Pages 187-194

  Sombroek, D ^a   Hofmann, T G ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CASPASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEASOME; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PUMA PROTEIN; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN;

APOPTOSIS; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL GROWTH; CELL TYPE; DNA DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STABILITY; GENE MUTATION; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TISSUE TYPES;

APOPTOSIS; CARRIER PROTEINS; CASPASES; DNA DAMAGE; HUMANS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 58249110508     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.154     Document Type: Review

References (81)

1. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408: 433-439.
2. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002; 297: 547-551.
3. Harper JW, Elledge SJ. The DNA damage response: Ten years after. Mol Cell 2007; 28: 739-745.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
5. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642.
6. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
7. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-168.
8. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-2196.
9. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434: 605-611.
10. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATR-ATRIP complex. Cell 2006; 124: 943-955.
11. Kumagai A, Dunphy WG. How cells activate ATR. Cell Cycle 2006; 5: 1265-1268.
12. Bartek J, Lukas J. DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol 2007; 19: 238-245.
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
14. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
15. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10: 431-442.
16. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
17. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
18. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4 1-10.
19. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002; 4: 11-19.
20. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004; 293: 311-320.
21. Dauth I, Kruger J, Hofmann TG. Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 2007; 67: 2274-2279.
22. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 849-862.
23. Kurihara A, Nagoshi H, Yabuki M, Okuyama R, Obinata M, Ikawa S. Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis. Genes Cells 2007; 12: 853-861.
24. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 1998; 273: 25875-25879.
25. Roscic A, Moller A, Calzado MA, Renner F, Wimmer VC, Gresko E et al Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol Cell 2006; 24: 77-89.
26. Link N, Chen P, Lu WJ, Pogue K, Chuong A, Mata M et al. A collective form of cell death requires homeodomain interacting protein kinase. J Cell Biol 2007; 178: 567-574.
27. Isono K, Nemoto K, Li Y, Takada Y, Suzuki R, Katsuki M et al. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol 2006; 26: 2758-2771.
28. Wiggins AK, Wei G, Doxakis E, Wong C, Tang AA, Zang K et al. Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. J Cell Biol 2004; 167: 257-267.
29. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 2003; 115: 177-186.
30. Zhang J, Pho V, Bonasera SJ, Holzmann J, Tang AT, Hellmuth J et al Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. Nat Neurosci 2007; 10: 77-86.
31. Calzado MA, Renner F, Roscic A, Schmitz ML. HIPK2: A versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 2007; 6: 139-143.
32. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: A multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 2007; 85: 411-418.
33. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J et al. HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 2007; 104: 13040-13045.
34. Pierantoni GM, Bulfone A, Pentimalli F, Fedele M, Iuliano R, Santoro M et al. The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun 2002; 290: 942-947.
35. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S et al. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene 2007; 26: 7231-7239.
36. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7: 899-910.
37. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S et al. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007; 117: 693-702.
38. Wee HJ, Voon DC, Bae SC, Ito Y. PEBP2{beta}/CBF{beta}-dependent phosphorylation of RUNX1 and p300 by HIPK2: Implications for leukemogenesis. Blood 2008, DOI: 10.1182/Blood-2008-01-134122.
39. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008; 27: 4745-4751.
40. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 2008; 67: 878-887.
41. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G et al. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 2001; 20: 6132-6141.
42. Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 2004; 23: 4583-4594.
43. Giraud S, Diaz-Latoud C, Hacot S, Textoris J, Bourette RP, Diaz JJ. US11 of herpes simplex virus type 1 interacts with HIPK2 and antagonizes HIPK2-induced cell growth arrest. J Virol 2004; 78: 2984-2993.
44. Doxakis E, Huang EJ, Davies AM. Homeodomain-interacting protein kinase-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol 2004; 14: 1761-1765.
45. Kim EJ, Park JS, Um SJ. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem 2002; 29: 29.
46. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005; 280: 25953-25959.
47. Ichwan SJ, Yamada S, Sumrejkanchanakij P, Ibrahim-Auerkari E, Eto K, Ikeda MA. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 2006; 25: 1216-1224.
48. Cecchinelli B, Porrello A, Lazzari C, Gradi A, Bossi G, D'Angelo M et al. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ 2006; 13: 1994-1997.
49. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W et al PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 2003; 63: 4310-4314.
50. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000; 2: 730-736.
51. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000; 19: 6185-6195.
52. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210.
53. Hofmann TG, Will H. Body language: The function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 2003; 10: 1290-1299.
54. Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 2003; 22: 9048-9057.
55. Krieghoff-Henning E, Hofmann TG. Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta 2008, doi:10.1016/ j.bbamcr.2008.07.002.
56. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007; 8: 1006-1016.
57. Moller A, Sirma H, Hofmann TG, Staege H, Gresko E, Ludi KS et al. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression. Oncogene 2003; 22: 8731-8737.
58. Li Q, Wang X, Wu X, Rui Y, Liu W, Wang J et al. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res 2007; 67: 66-74.
59. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85-94.
60. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 2003; 278 37722-37729.
61. Hofmann TG, Stollberg N, Schmitz ML, Will H. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 2003; 63: 8271-8277.
62. Wang SY, Iordanov M, Zhang Q. c-Jun NH2-terminal kinase promotes apoptosis by down-regulating the transcriptional co-repressor CtBP. J Biol Chem 2006; 281: 34810-34815.
63. Hofmann TG, Jaffray E, Stollberg N, Hay RT, Will H. Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification. J Biol Chem 2005; 280: 29224-29232.
64. Gresko E, Moller A, Roscic A, Schmitz ML. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability. Biochem Biophys Res Commun 2005; 329: 1293-1299.
65. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ et al. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 2008; 283 4682-4689.
66. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J et al. Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 2008; 10: 812-824.
67. Vasiliauskas D, Hancock S, Stern CD. SWiP-1: Novel SOCS box containing WD-protein regulated by signalling centres and by Shh during development. Mech Dev 1999; 82: 79-94.
68. Gresko E, Roscic A, Ritterhoff S, Vichalkovski A, Del Sal G, Schmitz ML. Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J 2006; 25: 1883-1894.
69. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99 9492-9497.
70. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 2007; 25: 739-750.
71. Matsuzawa S, Takayama S, Froesch BA, Zapata JM, Reed JC. p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: Suppression by BAG-1. EMBO J 1998; 17: 2736-2747.
72. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001; 7: 915-926.
73. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001; 7: 927-936.
74. Fiucci G, Beaucourt S, Duflaut D, Lespagnol A, Stumptner-Cuvelette P, Geant A et al. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc Natl Acad Sci USA 2004; 101: 3510-3515.
75. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
76. Carthew RW, Rubin GM. Seven in absentia, a gene required for specification of R7 cell fate in the Drosophila eye. Cell 1990; 63: 561-577.
77. Schmidt RL, Park CH, Ahmed AU, Gundelach JH, Reed NR, Cheng S et al Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res 2007; 67: 11798-11810.
78. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64: 993-998.
79. Safran M, Kaelin Jr WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-783.
80. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A et al Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 2004; 117: 941-952.
81. Aikawa Y, Nguyen LA, Isono K, Takakura N, Tagata Y, Schmitz ML et al Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 2006; 25: 3955-3965.